A Chinese expert consensus published in Portal Hypertension & Cirrhosis in 2026 standardizes a measurement that could change how liver fat is checked: ultrasound-derived fat fraction, or UDFF. Led by teams at Fudan University, the review and consensus panel examined the evidence for this noninvasive ultrasound technique, which estimates the percentage of fat in the liver from the signal reflected back by liver tissue, and the numbers are strong enough to matter.
The accuracy data are the headline. Across the reviewed studies, UDFF showed repeatability above 0.94, diagnostic accuracy of at least 0.90 in multiple studies, and a meta-analysis of more than 1,100 patients reported 90 percent sensitivity and 84 percent specificity. In several head-to-head comparisons it outperformed standard ultrasound grading, the controlled attenuation parameter, and common blood-based indices, which is a strong showing for a bedside tool.
Why does this matter? Liver biopsy is invasive and costly, and MRI, the gold standard for measuring fat, is expensive and not available in every clinic. UDFF runs on ultrasound machines that already sit in most imaging departments, which makes it a candidate for large-scale screening and routine monitoring, especially in settings where MRI and biopsy are hard to reach.
The consensus also sets diagnostic cut points, which is the part clinicians need to act consistently. Standardized thresholds mean two clinics reading the same patient should reach the same conclusion, which is the difference between a measurement and a standard. The panel drew on multicenter trials, biopsy comparisons, MRI-based analyses, and pediatric and special populations to build the reference points.
The comparison detail worth keeping: UDFF correlated strongly with MRI-PDFF, the imaging gold standard, and showed good agreement with biopsy results, while beating the controlled attenuation parameter and the fatty liver index in the reviewed evidence. That is a meaningful step up, because CAP is the tool many clinics currently use and its accuracy has limits at the extremes.
The honest limits are in the paper. Heterogeneity in reference standards and thinner data in some subpopulations mean the cut points will keep being refined, and the authors call for large multicenter studies using unified benchmarks. UDFF is also a fat measurement, not a fibrosis measurement, so it answers one question while stiffness scores answer another.
For a reader with fatty liver, the practical meaning is that monitoring may get easier. Instead of a biopsy or an MRI every time the fat number needs checking, an ultrasound measurement can track whether the plate and lifestyle changes are actually lowering liver fat, which is exactly the feedback loop that keeps people engaged with the friendly pattern this site rates.
The screening implication is the quiet advance. Fatty liver is underdiagnosed in primary care because the workup is heavy, and a cheap, repeatable ultrasound measurement could make routine screening feasible at scale. Early detection is the cheapest intervention in liver disease, and UDFF is one more step toward making it routine rather than exceptional.
The pediatric angle deserves a mention. The evidence reviewed included children, where biopsy and MRI are even harder to justify, and a noninvasive ultrasound measurement fits the pediatric setting well. Childhood fatty liver is rising, as this week’s global burden report showed, so a repeatable, child-friendly measurement tool is timely rather than academic.
The consensus also anchors monitoring during treatment. Whether the treatment is lifestyle, weight loss, or a medication, tracking the fat fraction over time is how progress is judged, and a standardized ultrasound measurement gives that tracking a consistent yardstick across clinics. Consistency is what turns a number into a trend a clinician can act on.
None of this replaces the clinician. The consensus standardizes a measurement, not a diagnosis or a treatment plan, and a person with elevated fat, stiffness, or symptoms needs the care team to interpret the combination of tests and decide the next step. The reader controls the plate and the follow-up; the imaging and the interpretation belong to the clinic.
The cost and access story is the part with the widest reach. MRI is not available everywhere, biopsy is not acceptable to everyone, and the current pathway leaves many patients unmeasured. A standardized ultrasound tool, on machines already in the building, closes part of that gap, which is why this consensus could matter more for public health than any single trial.
For a reader, the takeaway is that the future of liver monitoring is getting cheaper, safer, and more repeatable. The plate stays the daily lever, and the measurement gets easier to check, which is a genuinely good combination. Better tools do not change what to eat; they make it easier to see that eating well is working.
The standardization angle is the part that gives the tool its power. A measurement is only as good as its reference points, and the consensus panel’s cut points mean the same fat fraction can be interpreted the same way in different cities and different clinics. That consistency is what turns a useful technology into a standard of care, and it is why the review was worth publishing as a consensus rather than a single-center claim.
The comparison to CAP is worth a plain sentence. CAP is the tool many clinics already use, and the reviewed evidence showed UDFF outperforming it in several analyses, which suggests the next generation of ultrasound machines could make the better measurement the default one. Readers should not expect to see this overnight, but the direction is clear, and the consensus is the step that makes the direction real.
The dietary connection closes the loop. If liver fat can be measured cheaply and repeatably, then the response to the plate, the fiber, the unsaturated fat, and the reduced sugar load, can be tracked directly, which is the feedback a reader needs to stay motivated. The measurement is the mirror, the plate is the change, and the two together make the friendly pattern a visible, verifiable strategy rather than a leap of faith.
What is ultrasound-derived fat fraction?
UDFF is a noninvasive ultrasound technique that estimates the percentage of fat in the liver from the radiofrequency signal reflected back by liver tissue. It is cheaper than MRI and does not require a biopsy needle.
How accurate is it?
In the reviewed evidence, UDFF showed excellent repeatability above 0.94, diagnostic accuracy of at least 0.90 in multiple studies, and a meta-analysis of more than 1,100 patients reported 90 percent sensitivity and 84 percent specificity. It outperformed standard ultrasound grading and CAP in several comparisons.
Does this replace a biopsy?
It reduces the need for biopsy in routine assessment, and the consensus positions it for screening and monitoring. For uncertain or advanced cases, biopsy still has a role, and the test is a triage tool rather than the last word.